NextGen CAB-ADCs: Maximizing Safety & the Therapeutic Index

Time: 1:30 pm
day: Track B - Pre-Conf- PM


  • Overviewing the CAB platform to minimize antigen related toxicity by pH-selective binding in the tumor microenvironment
  • Optimizing linker selection for improved serum stability and tumor-targeted payload release
  • Discussing approaches to maximize the therapeutic index of ADCs